Boehringer & BridgeBio Seek EU Fast-Track Status; Enfortumab Vedotin Reverts To Standard Review

 
• By Neena Brizmohun

Applications for the accelerated assessment of planned EU marketing applications for two drugs are being considered by the European Medicines Agency.

Calendar Pages
An accelerated assessment can cut months off the EMA's drug review time • Source: Alamy

More from Europe

More from Geography